Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Section 6 of 6

References

177 sources

  1. AAAAI Choosing Wisely list (opens in a new tab)
  2. AAAAI Urticaria Measures Set (2015) (opens in a new tab)
  3. AAAAI/ACAAI JTF Chronic Urticaria Guideline Panel (2026) (opens in a new tab)
  4. Abdalla et al. (2026) (opens in a new tab)
  5. ACAAI JTF chronic urticaria guideline announcement (2026) (opens in a new tab)
  6. Agache et al. (2021) (opens in a new tab)
  7. Altayf et al. (2026) (opens in a new tab)
  8. Alvarado et al. (2022) (opens in a new tab)
  9. Alvarado et al. (2026) (opens in a new tab)
  10. Balachandar et al. (2026) (opens in a new tab)
  11. Balp et al. (2018a) (opens in a new tab)
  12. Balp et al. (2018b) (opens in a new tab)
  13. Balp et al. (2022) (opens in a new tab)
  14. Balp et al. (2025) (opens in a new tab)
  15. Bernstein et al. (2014) (opens in a new tab)
  16. Bernstein et al. (2025) (opens in a new tab)
  17. Broder et al. (2015) (opens in a new tab)
  18. Celldex AAAAI 2026 data release (2026) (opens in a new tab)
  19. Celldex AAD 2026 quality of life release (2026) (opens in a new tab)
  20. Celldex EAACI 2023 urticaria release (2023) (opens in a new tab)
  21. Celldex EAACI 2026 angioedema release (2026) (opens in a new tab)
  22. Celldex EMBARQ-CSU enrollment release (2026) (opens in a new tab)
  23. Celldex EMBARQ-CSU initiation release (2024) (opens in a new tab)
  24. Celldex EMBARQ-CSU topline release (2026) (opens in a new tab)
  25. Celldex eosinophilic esophagitis phase 2 results release (2025) (opens in a new tab)
  26. Celldex first quarter results release (2026) (opens in a new tab)
  27. Celldex Form 10-K (2026) (opens in a new tab)
  28. Celldex Form 10-Q, third quarter (2026) (opens in a new tab)
  29. Celldex fourth quarter 2021 results release (2022) (opens in a new tab)
  30. Celldex fourth quarter 2025 results release (2026) (opens in a new tab)
  31. Celldex phase 1b CSU AAAAI release (2023) (opens in a new tab)
  32. Celldex phase 1b CSU EAACI release (2022) (opens in a new tab)
  33. Celldex phase 1b CSU initiation release (2020) (opens in a new tab)
  34. Celldex phase 2 CSU 52-week results release (2024) (opens in a new tab)
  35. Celldex phase 2 CSU angioedema release (2024) (opens in a new tab)
  36. Celldex phase 2 CSU first patient dosed release (2022) (opens in a new tab)
  37. Celldex presentation, EMBARQ-CSU topline results call (2026) (opens in a new tab)
  38. Celldex prurigo nodularis phase 2 results release (2026) (opens in a new tab)
  39. Celldex second quarter results release (2026) (opens in a new tab)
  40. Celldex subcutaneous formulation study release (2021) (opens in a new tab)
  41. Celldex third quarter results release (2026) (opens in a new tab)
  42. Chansakulporn et al. (2014) (opens in a new tab)
  43. Chu et al. (2025a) (opens in a new tab)
  44. Chu et al. (2025b) (opens in a new tab)
  45. Chu et al. (2026) (opens in a new tab)
  46. Chung et al. (2020) (opens in a new tab)
  47. Church et al. (2018) (opens in a new tab)
  48. ClinicalTrials.gov NCT04146129 (opens in a new tab)
  49. ClinicalTrials.gov NCT04538794 (opens in a new tab)
  50. ClinicalTrials.gov NCT05031624 (opens in a new tab)
  51. ClinicalTrials.gov NCT05368285 (opens in a new tab)
  52. ClinicalTrials.gov NCT06445023 (opens in a new tab)
  53. ClinicalTrials.gov NCT06445023 record history (opens in a new tab)
  54. ClinicalTrials.gov NCT06455202 (opens in a new tab)
  55. ClinicalTrials.gov NCT06455202 record history (opens in a new tab)
  56. ClinicalTrials.gov NCT07256392 (opens in a new tab)
  57. Confino-Cohen et al. (2012) (opens in a new tab)
  58. DeLong et al. (2008) (opens in a new tab)
  59. Doğan et al. (2026) (opens in a new tab)
  60. Dupixent prescribing information (2026) (opens in a new tab)
  61. Ertas et al. (2018) (opens in a new tab)
  62. Eun et al. (2019) (opens in a new tab)
  63. Fijen et al. (2023) (opens in a new tab)
  64. Fok et al. (2021) (opens in a new tab)
  65. Fricke et al. (2020) (opens in a new tab)
  66. Geissbühler et al. (2025) (opens in a new tab)
  67. Genentech Xolair cost page (2026) (opens in a new tab)
  68. Gericke et al. (2017) (opens in a new tab)
  69. Giménez-Arnau et al. (2025) (opens in a new tab)
  70. Giménez-Arnau et al. (2026a) (opens in a new tab)
  71. Giménez-Arnau et al. (2026b) (opens in a new tab)
  72. Gonçalo et al. (2021) (opens in a new tab)
  73. Graham et al. (2016) (opens in a new tab)
  74. Guillén-Aguinaga et al. (2016) (opens in a new tab)
  75. Hawro et al. (2018) (opens in a new tab)
  76. Healio (2026) (opens in a new tab)
  77. Hu et al. (2026) (opens in a new tab)
  78. Huang et al. (2025) (opens in a new tab)
  79. Jahn et al. (2026) (opens in a new tab)
  80. Jang and Lee (2026) (opens in a new tab)
  81. Jang et al. (2025) (opens in a new tab)
  82. Kanters et al. (2018) (opens in a new tab)
  83. Kaplan et al. (2013) (opens in a new tab)
  84. Kim et al. (2022) (opens in a new tab)
  85. Kocatürk et al. (2026a) (opens in a new tab)
  86. Kocatürk et al. (2026b) (opens in a new tab)
  87. Kolkhir et al. (2017a) (opens in a new tab)
  88. Kolkhir et al. (2017b) (opens in a new tab)
  89. Kolkhir et al. (2021) (opens in a new tab)
  90. Kolkhir et al. (2022a) (opens in a new tab)
  91. Kolkhir et al. (2022b) (opens in a new tab)
  92. Kolkhir et al. (2022c) (opens in a new tab)
  93. Kolkhir et al. (2023) (opens in a new tab)
  94. Kolkhir et al. (2025) (opens in a new tab)
  95. Kolkhir et al. (2026) (opens in a new tab)
  96. Konstantinou and Konstantinou (2019) (opens in a new tab)
  97. Kulthanan et al. (2018) (opens in a new tab)
  98. Kulthanan et al. (2019) (opens in a new tab)
  99. Lapi et al. (2016) (opens in a new tab)
  100. Lapi et al. (2026) (opens in a new tab)
  101. Mathias et al. (2012) (opens in a new tab)
  102. Maurer et al. (2013) (opens in a new tab)
  103. Maurer et al. (2017) (opens in a new tab)
  104. Maurer et al. (2020) (opens in a new tab)
  105. Maurer et al. (2023a) (opens in a new tab)
  106. Maurer et al. (2023b) (opens in a new tab)
  107. Maurer et al. (2023c) (opens in a new tab)
  108. Maurer et al. (2024a) (opens in a new tab)
  109. Maurer et al. (2024b) (opens in a new tab)
  110. Maurer et al. (2024c) (opens in a new tab)
  111. Maurer et al. (2024d) (opens in a new tab)
  112. Maurer et al. (2024e) (opens in a new tab)
  113. Maurer et al. (2025a) (opens in a new tab)
  114. Maurer et al. (2025b) (opens in a new tab)
  115. Metz et al. (2024) (opens in a new tab)
  116. Metz et al. (2025a) (opens in a new tab)
  117. Metz et al. (2025b) (opens in a new tab)
  118. Metz et al. (2025c) (opens in a new tab)
  119. Metz et al. (2025d) (opens in a new tab)
  120. Metz et al. (2025e) (opens in a new tab)
  121. Metz et al. (2025f) (opens in a new tab)
  122. Metz et al. (2026a) (opens in a new tab)
  123. Metz et al. (2026b) (opens in a new tab)
  124. Metz et al. (2026c) (opens in a new tab)
  125. Metz et al. (2026d) (opens in a new tab)
  126. Metz et al. (2026e) (opens in a new tab)
  127. Moñino-Romero et al. (2023) (opens in a new tab)
  128. Moñino-Romero et al. (2025) (opens in a new tab)
  129. Mosnaim et al. (2026a) (opens in a new tab)
  130. Mosnaim et al. (2026b) (opens in a new tab)
  131. Mosnaim et al. (2026c) (opens in a new tab)
  132. Mtibaa et al. (2026) (opens in a new tab)
  133. Muñoz et al. (2026a) (opens in a new tab)
  134. Muñoz et al. (2026b) (opens in a new tab)
  135. NICE remibrutinib draft guidance (2026) (opens in a new tab)
  136. NICE TA339 (2015) (opens in a new tab)
  137. Novartis Rhapsido savings and support page (2026) (opens in a new tab)
  138. O'Donnell et al. (1997) (opens in a new tab)
  139. Ocadiz-Ruiz et al. (2026) (opens in a new tab)
  140. Ohanyan et al. (2017) (opens in a new tab)
  141. Omlyclo prescribing information (2025) (opens in a new tab)
  142. Oregon PDAB Xolair affordability review (2026) (opens in a new tab)
  143. Regeneron Dupixent Colorado price disclosure (2026) (opens in a new tab)
  144. Rhapsido prescribing information (2026) (opens in a new tab)
  145. Riedl et al. (2025) (opens in a new tab)
  146. Riedl et al. (2026) (opens in a new tab)
  147. Ryan et al. (2022) (opens in a new tab)
  148. Saini et al. (2015) (opens in a new tab)
  149. Saini et al. (2025) (opens in a new tab)
  150. Schoepke et al. (2019) (opens in a new tab)
  151. Shaker et al. (2020) (opens in a new tab)
  152. Soong et al. (2025a) (opens in a new tab)
  153. Soong et al. (2025b) (opens in a new tab)
  154. Stull et al. (2017) (opens in a new tab)
  155. Sussman et al. (2018) (opens in a new tab)
  156. Tan et al. (2025) (opens in a new tab)
  157. Terhorst-Molawi et al. (2023) (opens in a new tab)
  158. Tharp et al. (2019) (opens in a new tab)
  159. Tsai et al. (2022) (opens in a new tab)
  160. Viegas et al. (2025) (opens in a new tab)
  161. Weller et al. (2013) (opens in a new tab)
  162. Weller et al. (2014) (opens in a new tab)
  163. Weller et al. (2020a) (opens in a new tab)
  164. Weller et al. (2020b) (opens in a new tab)
  165. Weller et al. (2025a) (opens in a new tab)
  166. Weller et al. (2025b) (opens in a new tab)
  167. Wertenteil et al. (2019) (opens in a new tab)
  168. WHO Proposed INN List 125 (2021) (opens in a new tab)
  169. Williams et al. (2018a) (opens in a new tab)
  170. Williams et al. (2018b) (opens in a new tab)
  171. Xiong et al. (2025) (opens in a new tab)
  172. Xolair prescribing information (2026) (opens in a new tab)
  173. Yosipovitch et al. (2026) (opens in a new tab)
  174. Yücel and Ünal (2026) (opens in a new tab)
  175. Zhao et al. (2025) (opens in a new tab)
  176. Zuberbier et al. (2010) (opens in a new tab)
  177. Zuberbier et al. (2026) (opens in a new tab)